Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy:: The GVAX™ vaccine for prostate cancer

被引：127

作者：

Simons, Jonathan W. ^{[1
]}

Sacks, Natalie

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Cell Genesys Inc, San Francisco, CA 94080 USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2006年 / 24卷 / 05期

关键词：

GM-CSF; cellular immunotherapy; dendritic cell vaccine;

D O I：

10.1016/j.urolonc.2005.08.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

New approaches to therapeutics of advanced prostate cancer are urgently needed. GVAX (R) (granulocyte-macrophage colony-stimulating factor [GM-CSF] gene transduced irradiated prostate cancer vaccine cells) offers the possibility that "host versus prostate cancer" immune responses can be generated in prostate cancer patients. Critical components involve the dendritic cell loading of candidate prostate cancer lymph node metastasis and candidate bone metastasis antigens derived from irradiated prostate cancer whole cells. GM-CSF acts at the vaccination site to enhance activation dendritic cells and antigen presentation to both the B-cell and T-cell arms of the immune system. GVAX (R) preclinically-in both rat and transgenic prostate cancer models-has antitumor activity which has informed early clinical trial designs. Clinical investigations reviewed in this report suggest that vaccination is safe and immune tolerance can be broken against prostate cancer. Multi-institutional phase III investigation is currently underway to evaluate the impact of allogeneic prostate GVAX (R) cellular immunotherapy on time to progression and overall survival in hormone refractory prostate cancer. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：419 / 424

页数：6

共 20 条

[1] Gene therapy and molecular immunology unite to give new life to cancer immunotherapy [J].

Ando, D .

MOLECULAR THERAPY, 2002, 5 (06) :665-667

[2] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].

Bubley, GJ ;

Carducci, M ;

Dahut, W ;

Dawson, N ;

Daliani, D ;

Eisenberger, M ;

Figg, WD ;

Freidlin, B ;

Halabi, S ;

Hudes, G ;

Hussain, M ;

Kaplan, R ;

Myers, C ;

Oh, W ;

Petrylak, DP ;

Reed, E ;

Roth, B ;

Sartor, O ;

Scher, H ;

Simons, J ;

Sinibaldi, V ;

Small, EJ ;

Smith, MR ;

Trump, DL ;

Vollmer, R ;

Wilding, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467

[3] VACCINATION WITH IRRADIATED TUMOR-CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTITUMOR IMMUNITY [J].

DRANOFF, G ;

JAFFEE, E ;

LAZENBY, A ;

GOLUMBEK, P ;

LEVITSKY, H ;

BROSE, K ;

JACKSON, V ;

HAMADA, H ;

PARDOLL, D ;

MULLIGAN, RC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3539-3543

[4] Leveraging the activity of tumor vaccines with cytotoxic chemotherapy [J].

Emens, LA ;

Jaffee, EM .

CANCER RESEARCH, 2005, 65 (18) :8059-8064

[5]

Fuchs E J, 1996, Semin Immunol, V8, P271, DOI 10.1006/smim.1996.0035

[6] The central role of CD4+ T cells in the antitumor immune response [J].

Hung, K ;

Hayashi, R ;

Lafond-Walker, A ;

Lowenstein, C ;

Pardoll, D ;

Levitsky, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2357-2368

[7]

Hurwitz AA, 2000, CANCER RES, V60, P2444

[8] Enhanced immune priming with spatial distribution of paracrine cytokine vaccines [J].

Jaffee, EM ;

Thomas, MC ;

Huang, AYC ;

Hauda, KM ;

Levitsky, HI ;

Pardoll, DM .

JOURNAL OF IMMUNOTHERAPY, 1996, 19 (03) :176-183

[9] USE OF MURINE MODELS OF CYTOKINE-SECRETING TUMOR VACCINES TO STUDY FEASIBILITY AND TOXICITY ISSUES CRITICAL TO DESIGNING CLINICAL-TRIALS [J].

JAFFEE, EM ;

LAZENBY, A ;

MEURER, J ;

MARSHALL, F ;

HAUDA, KM ;

COUNTS, C ;

HURWITZ, H ;

SIMONS, JW ;

LEVITSKY, HI ;

PARDOLL, DM .

JOURNAL OF IMMUNOTHERAPY, 1995, 18 (01) :1-9

[10] Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy [J].

Kwon, ED ;

Foster, BA ;

Hurwitz, AA ;

Madias, C ;

Allison, JP ;

Greenberg, NM ;

Burg, MB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15074-15079

← 1 2 →